

GlobelImmune Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 28-Apr-2015

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drug Pipeline Detail..... 11

 Phase 2 Clinical..... 12

 Discovery..... 29

[Return to Table of Contents](#)

GlobelImmune Inc

COMPANY OVERVIEW

Company Name	GlobelImmune Inc
Parent Company Name	GlobelImmune Inc
Website	http://www.globeimmune.com/
Country	US
Number of Drugs in Active Development	6
Number of Inactive Drugs	12
Number of Patents as Owner	20
Number of Patents as Third Party	2
Number of Deals	9
Key Indications	Breast tumor,Chordoma,HIV infection,Hepatitis D virus infection,Mycobacterium tuberculosis infection,Non-small-cell lung cancer,Pancreas tumor,Colorectal tumor,Medullary thyroid cancer,Hepatitis B
Key Target-based Actions	Hepatitis C virus NS3 protease modulator,Mucin 1 stimulator,CD66e modulator,Brachyury protein modulator,CD95 agonist,Epidermal growth factor receptor modulator,HIV GAG protein modulator,PARP inhibitor,Protease inhibitor,Ras GTPase modulator,SETX gene modulator
Key Technologies	Yeast recombinant,Biological therapeutic,Antigen presentation system,Parenteral formulation unspecified,Tumor antigen therapeutic,Subcutaneous formulation,Small molecule therapeutic,Protein fusion,Viral core protein,Antigen,Drug combination,Peptide,Tumor antigen

COMPANY PROFILE

SUMMARY

GlobelImmune Inc is a biopharmaceutical company which is engaged in the discovery, development and manufacturing of potent, targeted molecular immunotherapies, named Tarmogens, for the treatment of cancer and infectious diseases. Tarmogens are whole, heat-killed recombinant *Saccharomyces cerevisiae* yeast which has been genetically modified to express protein targets. They taken up by antigen presenting cells, and stimulate a cytotoxic T lymphocytes against cells expressing the desired target.

COMPANY LOCATION

In December 2005, GlobelImmune relocated its headquarters to Louisville, CO.

TECHNOLOGY INFORMATION

Tarmogens are whole, heat-killed, recombinant *Saccharomyces cerevisiae* engineered to produce one or more target disease proteins or antigens that stimulate the immune system against diseased cells.

LICENSING AGREEMENTS

In May 2009, GlobelImmune granted exclusive license to all their oncology programs, including GI-4000 immunotherapies, to Celgene, for which GlobelImmune will receive a \$40 million upfront payment from Celgene. GlobelImmune will conduct the early development of the product candidates through certain pre-defined endpoints. Celgene will have the option to obtain an exclusive worldwide license to develop and commercialize these immunotherapy product candidates. GlobelImmune is eligible to receive over \$500 million in development and regulatory milestones, double-digit royalties and additional milestone payments based on net sales of the licensed product candidates.

In July 2008, GlobelImmune and the National Cancer Institute (NCI) at the National Institutes of Health (NIH) signed a CRADA to jointly develop Tarmogen based immunotherapy products for cancer. GlobelImmune would use its Tarmogen technology to develop the products which would express cancer antigens provided by the NIH. The NIH would conduct and fund preclinical and early clinical development of the product candidates. CEA (carcinoembryonic antigen) was the

[Return to Table of Contents](#)



first cancer antigen to be evaluated in this collaboration.

In January 2005, GlobelImmune and MycoLogics Inc signed a non-exclusive research license and option agreement. MycoLogics was to undertake proof-of-concept preclinical tests of vaccines targeting aspergillosis, coccidioidmycosis, cryptococcosis leishmaniasis, discovered using GlobelImmune's Tarmogen technology. The research was supported by NIH SBIR and STTR awards.

FINANCIAL

In July 2014, the company planned to conduct an IPO of 1.5 million shares priced at \$10 each for gross proceeds of \$15 million. Underwriters would be granted a 45-day overallotment option to purchase up to 225,000 additional shares. The stock was approved to be listed on the NASDAQ Capital Market and trading of shares began under the ticker symbol 'GBIM'. At that time, the offering was expected to close on July 08, 2014. Later that month, the company raised gross proceeds of \$17.25 million from the offering of 1.725 million shares.

In July 2012, the company filed a common stock IPO registration statement with the US Security and Exchange Commission. At that time, the company also filed for its common stock to be listed on the NASDAQ Global Market under the symbol "GBIM".

In January 2010, GlobelImmune raised \$17.5 million from a series E preferred stock financing round.

In September 2007, GlobelImmune closed a \$41.2 million series C preferred stock financing round.

In January 2006, GlobelImmune completed a second closing of its series B preferred stock financing, raising a further \$4.1 million in addition to the previous \$34.3 million. The Company would use the funds to finish a phase II trial of GI-4000 for pancreatic cancer, and a phase Ib trial of GI-5005 for chronic hepatitis C infection.

In June 2003, GlobelImmune closed a series A preferred venture financing round. The round provided for up to \$8 million in two tranches, with closure of the second tranche dependent on achievement of certain milestones.

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




[Return to Table of Contents](#)

Drugs by Indication Table

Indication	Active	Inactive	Total
Neoplasm	3	6	9
Infectious disease	3	6	9
Gastrointestinal disease	2	2	4
Respiratory disease	2	2	4
Inflammatory disease	1	2	3
Endocrine disease	2	1	3
Dermatological disease	0	2	2
Gynecology and obstetrics	1	1	2
Immune disorder	0	2	2
Nutritional disorder	0	1	1
Musculoskeletal disease	1	0	1
Hematological disease	0	1	1
Neurological disease	0	1	1

Drugs by Highest Status

Active Drugs by Highest Status Chart



[Return to Table of Contents](#)

Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	3
Discovery	3
Discontinued	1
No Development Reported	11

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Discovery/Design	1	0	0	0	1
Drug - Funding	3	0	0	0	3
Drug - CRADA	1	0	0	0	1
Drug - Early Research/Development	0	0	1	0	1
Drug - Development/Commercialization License	1	0	0	0	1
Drug - Development Services	1	0	1	0	2

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Neoplasm	3	7
Gastrointestinal disease	0	5
Respiratory disease	0	2
Inflammatory disease	0	2
Infectious disease	0	2
Endocrine disease	1	1
Musculoskeletal disease	1	1

Trials by Phase

Phase	Ongoing	All
Phase 2	2	6
Phase 1	1	3

[Return to Table of Contents](#)



Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Cardiovascular disease	0	1	1
Endocrine disease	3	0	3
Gastrointestinal disease	7	0	7
Genitourinary disease	2	0	2
Hematological disease	0	1	1
Degeneration	1	0	1
Andrology	1	0	1
Immune disorder	1	1	2
Musculoskeletal disease	1	0	1
Neoplasm	11	0	11
Ocular disease	0	1	1
Neurological disease	2	1	3
Nutritional disorder	1	0	1
Prophylaxis	1	0	1
Respiratory disease	5	0	5
Infectious disease	15	1	16
Inflammatory disease	7	1	8
Gynecology and obstetrics	2	0	2
Dermatological disease	1	0	1

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)



PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

GI-4000

GI-4000 SNAPSHOT

Drug Name	GI-4000
Key Synonyms	
Originator Company	GlobelImmune Inc
Active Companies	GlobelImmune Inc
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Non-small-cell lung cancer;Pancreas tumor;Colorectal tumor
Target-based Actions	Ras GTPase modulator
Other Actions	Recombinant fungal vector vaccine;Anticancer;Therapeutic vaccine
Technologies	Tumor antigen therapeutic;Biological therapeutic;Subcutaneous formulation;Yeast recombinant;Antigen presentation system
Last Change Date	09-Apr-2014

GI-4000 DEVELOPMENT PROFILE

SUMMARY

GlobelImmune (formerly CERES) is developing GI-4000, the lead from a Tarmogen vaccine program based on inactivated *Saccharomyces cerevisiae* that deliver four antigens correlating to seven tumor-associated mutations in the Ras protein, for the potential sc treatment of cancer, including pancreatic cancer, non-small-cell lung cancer (NSCLC), colorectal cancer,. In June 2006, the company began a phase II trial of GI-4000 for pancreatic cancer ; by November 2013, the study had been completed. In September 2007, two additional phase II trials were planned ; in March 2008, a phase IIa NSCLC trial began ; by November 2013, data had been reported. By April 2009, the vaccine was in phase II trials for colorectal cancer ; in October 2011, a phase II trial in combination with bevacizumab was initiated in patients with colorectal cancer and was expected to be completed in October 2014; by June 2013, the trial was ongoing. In October 2007, the company was seeking to outlicense GI-4000. In May 2009, an exclusive license option to all GlobelImmune's oncology programs, including GI-4000, was granted to Celgene.

The company was previously investigating GI-4014, GI-4015, and GI-4016 from the same series; however, no further development was reported.

GI-4000 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
---------	------------	---------	--------------------	------

[Return to Table of Contents](#)



Company	Indication	Country	Development Status	Date
Globelmmune Inc	Colorectal tumor	US	Phase 2 Clinical	16-Apr-2009
Globelmmune Inc	Non-small-cell lung cancer	US	Phase 2 Clinical	19-Mar-2008
Globelmmune Inc	Pancreas tumor	India	Phase 2 Clinical	09-Jun-2006
Globelmmune Inc	Pancreas tumor	US	Phase 2 Clinical	08-Jun-2006

GI-4000 DRUG NAMES

Names	Type
GI-4016	Research Code
CERES-Vax vaccine delivery system (cancer)	
GI-4015	Research Code
GI-4000 series (anticancer vaccine), Globelmmune	
GI-4000	Research Code
GI-4014	Research Code
vaccine delivery system (cancer), Globelmmune	
GI-4000 series (Ras), Globelmmune	
GI-4000 series (anticancer vaccine, Tarmogen), Globelmmune	

GI-4000 CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Pancreas tumor											
0	0	0	0	0	1	0	2	0	0	0	3
Non-small-cell lung cancer											
0	0	0	0	0	1	0	1	0	0	0	2
Colorectal tumor											
0	0	0	0	0	0	0	1	0	0	0	1

[Return to Table of Contents](#)

Metastatic colorectal cancer											
0	0	0	0	0	1	0	0	0	0	0	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	3	0	2	0	0	0	5

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

GI-4000 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




[Return to Table of Contents](#)

Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Globelimmune Inc	3	0	1	0	4
US Government	0	0	2	0	2
Biodesix Inc	1	0	0	0	1
Celgene Corp	0	0	1	0	1

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Funding	2	0	2
Drug - Development Services	1	0	1
Drug - Discovery/Design	1	0	1

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
GlobelImmune Inc	3	1	3
Biodesix Inc	1	0	1
University of Colorado System	1	1	1
Individual	1	0	1
Celgene Corp	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
General interest	2
Component of Combination	1
Product	1

GI-6207

GI-6207 SNAPSHOT

Drug Name	GI-6207
Key Synonyms	
Originator Company	GlobelImmune Inc
Active Companies	Celgene Corp;GlobelImmune Inc;National Cancer Institute
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Medullary thyroid cancer
Target-based Actions	CD66e modulator
Other Actions	Therapeutic vaccine;Anticancer;Recombinant vector vaccine
Technologies	Biological therapeutic;Subcutaneous formulation;Yeast recombinant
Last Change Date	09-Apr-2014

GI-6207 DEVELOPMENT PROFILE

SUMMARY

GlobelImmune, in collaboration with Celgene, and the NCI, is developing GI-6207, a Tarmogen vaccine based on inactivated *Saccharomyces cerevisiae* genetically modified to express CEA, for the potential sc treatment of cancer,. In February 2013, a phase II trial for recurrent medullary thyroid cancer was initiated in the US ; in March 2014, the trial was ongoing.

GI-6207 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Celgene Corp	Medullary thyroid cancer	US	Phase 2 Clinical	29-Aug-2013
GlobelImmune Inc	Medullary thyroid cancer	US	Phase 2 Clinical	28-Feb-2013
National Cancer Institute	Medullary thyroid cancer	US	Phase 2 Clinical	28-Feb-2013

[Return to Table of Contents](#)



GI-6207 DRUG NAMES

Names	Type
CEA-expressing <i>Saccharomyces cerevisiae</i> -based cancer vaccine (Tarmogen), GlobelImmune/NCI/Celgene	
CEA-expressing <i>Saccharomyces cerevisiae</i> -based cancer vaccine (Tarmogen), GlobelImmune/NCI	
GI-6207	Research Code

GI-6207 CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Medullary thyroid cancer											
0	0	0	0	1	1	0	0	0	0	1	1
Carcinoma											
0	0	0	0	0	0	0	1	0	0	0	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	1	1	0	1	0	0	1	2

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0


[Return to Table of Contents](#)



GI-6207 DEALS AND PATENTS

DEALS


Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
GlobelImmune Inc	3	0	0	0	3
US Government	0	0	2	0	2
Celgene Corp	0	0	1	0	1

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Discovery/Design	1	0	1
Drug - CRADA	1	0	1
Drug - Funding	1	0	1

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
University of Colorado System	1	1	1
GlobelImmune Inc	1	1	1
Individual	1	0	1
Celgene Corp	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
General interest	1

[Return to Table of Contents](#)

GI-6301

GI-6301 SNAPSHOT

Drug Name	GI-6301
Key Synonyms	
Originator Company	GlobelImmune Inc
Active Companies	Celgene Corp;GlobelImmune Inc
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Breast tumor;Chordoma
Target-based Actions	Brachyury protein modulator
Other Actions	Recombinant fungal vector vaccine;Therapeutic vaccine;Anticancer;Immunostimulant
Technologies	Biological therapeutic;Parenteral formulation unspecified;Yeast recombinant;Antigen presentation system
Last Change Date	23-Apr-2015

GI-6301 DEVELOPMENT PROFILE

SUMMARY

GlobelImmune, in collaboration with Celgene, is developing a lead from GI-6300 program, GI-6301, a Tarmogen vaccine containing the brachyury antigen, for the potential treatment of cancer, including triple negative breast cancer and chordoma,. In April 2015, the patient enrollment in a phase II chordoma trial in combination with the radiation therapy was initiated. At that time, the study was expected to be completed in March 2022. In January 2012, a phase I trial began for breast cancer.

GI-6301 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Celgene Corp	Chordoma	US	Phase 2 Clinical	22-Apr-2015
GlobelImmune Inc	Chordoma	US	Phase 2 Clinical	22-Apr-2015
Celgene Corp	Breast tumor	US	Phase 1 Clinical	29-Aug-2013
GlobelImmune Inc	Breast tumor	US	Phase 1 Clinical	26-Jan-2012

[Return to Table of Contents](#)



GI-6301 DRUG NAMES

Names	Type
GI-6300	Research Code
GI-6301	Research Code
Tarmogen vaccine (triple negative breast cancer), GlobelImmune/Celgene	
Tarmogen vaccine (triple negative breast cancer), GlobelImmune	

GI-6301 CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Solid tumor											
0	0	0	0	0	0	1	1	0	0	1	1
Chordoma											
0	0	0	0	1	1	0	0	0	0	1	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	1	1	1	1	0	0	2	2

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0


[Return to Table of Contents](#)



GI-6301 DEALS AND PATENTS

DEALS


Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
GlobelImmune Inc	2	0	0	0	2
US Government	0	0	1	0	1
Celgene Corp	0	0	1	0	1

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - CRADA	1	0	1
Drug - Discovery/Design	1	0	1

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
US Government	3	0	3
GlobelImmune Inc	2	0	2
Kite Pharma Inc	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
General interest	2
New use	1

GI-18000

GI-18000 SNAPSHOT

Drug Name	GI-18000
Key Synonyms	
Originator Company	GlobelImmune Inc
Active Companies	GlobelImmune Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Hepatitis D virus infection
Target-based Actions	
Other Actions	Unspecified drug target;Antiviral;Anti-inflammatory
Technologies	Biological therapeutic;Parenteral formulation unspecified;Yeast recombinant;Antigen presentation system
Last Change Date	19-Nov-2013

GI-18000 DEVELOPMENT PROFILE

SUMMARY

GlobelImmune is investigating GI-18000, based on company's Tarmogen platform, for the potential treatment of Hepatitis Delta viral infection. In September 2012, the drug was listed as being in preclinical development ; in November 2013, this was still the case.

GI-18000 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
GlobelImmune Inc	Hepatitis D virus infection	US	Discovery	18-Sep-2012

GI-18000 DRUG NAMES


Names	Type
GI-18000	Research Code

[Return to Table of Contents](#)



PATENTS


Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
GlobelImmune Inc	2	0	2

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
New use	1
General interest	1

[Return to Table of Contents](#)

GI-2010

GI-2010 SNAPSHOT

Drug Name	GI-2010
Key Synonyms	
Originator Company	GlobelImmune Inc
Active Companies	GlobelImmune Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	HIV infection
Target-based Actions	HIV GAG protein modulator
Other Actions	Recombinant fungal vector vaccine;Therapeutic vaccine;Antiviral;Immunostimulant
Technologies	Biological therapeutic;Parenteral formulation unspecified;Yeast recombinant;Antigen presentation system;Viral core protein
Last Change Date	19-Nov-2013

GI-2010 DEVELOPMENT PROFILE

SUMMARY

GlobelImmune is investigating GI-2010, a Tarmogen vaccine based on recombinant *Saccharomyces cerevisiae* genetically modified to express the gag protein of HIV, for the potential treatment of HIV infection . In September 2011, the vaccine was listed as being in preclinical development ; in November 2013, this was still the case.

The vaccine system, formerly termed the CERES-Vax vaccine delivery system, is also being investigated for carcinoma.

GI-2010 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
GlobelImmune Inc	HIV infection	US	Discovery	14-Jun-2001

[Return to Table of Contents](#)




GI-2010 DRUG NAMES

Names	Type
GI-004	Research Code
HIVAX-GS	
HIVAX-2	
GI-2010	Research Code
HIV GAG protein modulator (HIV infection), GlobelImmune Inc	
vaccine delivery system (HIV), GlobelImmune	
CERES-Vax vaccine delivery system (HIV)	

GI-2010 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
GlobelImmune Inc	1	0	0	0	1
US Government	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Funding	1	0	1

PATENTS


Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
GlobelImmune Inc	2	0	2

Patents by Drug Relationship Type Chart



[Return to Table of Contents](#)

Patents by Drug Relationship Type Table

Drug Relationship	Total
General interest	1
Formulation	1

[Return to Table of Contents](#)

GI-19000

GI-19000 SNAPSHOT

Drug Name	GI-19000
Key Synonyms	
Originator Company	GlobelImmune Inc
Active Companies	GlobelImmune Inc;Colorado State University
Inactive Companies	
Highest Status	Discovery
Active Indications	Mycobacterium tuberculosis infection
Target-based Actions	
Other Actions	Antibacterial;Therapeutic vaccine;Unspecified drug target;Prophylactic vaccine
Technologies	Yeast recombinant;Biological therapeutic;Parenteral formulation unspecified
Last Change Date	20-Jan-2015

GI-19000 DEVELOPMENT PROFILE

SUMMARY

GlobelImmune and the Colorado State University are investigating GI-19000, a recombinant yeast based vaccine, based on GlobelImmune's Tarmogen platform, for the potential prevention and treatment of Mycobacterium tuberculosis infection,. In June 2013, the drug was listed as being in preclinical development. In July 2014, development was ongoing.

GI-19000 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Colorado State University	Mycobacterium tuberculosis infection	US	Discovery	22-Aug-2013
GlobelImmune Inc	Mycobacterium tuberculosis infection	US	Discovery	13-Jun-2013

GI-19000 DRUG NAMES

Names	Type
GI-19000	Research Code


[Return to Table of Contents](#)



GI-19000 DEALS AND PATENTS

DEALS


Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
GlobelImmune Inc	1	0	1	0	2
Colorado State University	1	0	0	0	1
US Government	0	0	1	0	1

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Funding	1	0	1
Drug - Early Research/Development	1	0	1

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
GlobelImmune Inc	2	0	2
Colorado State University	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
General interest	1
Tentative	1

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

